Immuron Ltd (IMRN)
NASDAQ:IMRN
Want to see IMRN full AI Analyst Report?
Top Page
Immuron
(NASDAQ:IMRN)
Select Model
Select Model
Rating:47Neutral
Price Target:
$0.94
▲(15.00% Upside)
Action:UpgradedDate:04/19/26
The score is held down primarily by weak financial performance (declining revenue, large losses, and negative operating/free cash flow), partially offset by improving technical momentum (price above key short-term averages and positive MACD). Valuation contributes limited support due to a negative P/E and no dividend yield provided.
Positive Factors
Core product revenue growth & portfolio expansion
Sustained Travelan sales growth and the national ProIBS launch broaden Immuron’s recurring OTC gastrointestinal franchise. A growing, retail-distributed consumer base (pharmacy, Amazon, digital channels) creates a steadier revenue foundation and de-risks reliance on clinical-stage programs.
Negative Factors
Declining consolidated revenue
A reported -11% revenue decline is a durable concern: shrinking top-line reduces operating leverage and makes it harder to cover fixed costs. Even pockets of product growth may be offset by other declines or one-off items, limiting progress toward sustainable profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Core product revenue growth & portfolio expansion
Sustained Travelan sales growth and the national ProIBS launch broaden Immuron’s recurring OTC gastrointestinal franchise. A growing, retail-distributed consumer base (pharmacy, Amazon, digital channels) creates a steadier revenue foundation and de-risks reliance on clinical-stage programs.
Read all positive factors
Immuron (IMRN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.26M
Dividend YieldN/A
Average Volume (3M)75.95K
Price to Earnings (P/E)―
Beta (1Y)0.08
Revenue Growth11.90%
EPS Growth43.46%
CountryUS
Employees7
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.20
Shares Outstanding8,166,340
10 Day Avg. Volume112,552
30 Day Avg. Volume75,952
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.90
Price to Sales (P/S)2.09
P/FCF Ratio-2.49
Enterprise Value/Market Cap-0.35
Enterprise Value/Revenue-0.28
Enterprise Value/Gross Profit-0.44
Enterprise Value/Ebitda0.38
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)$6.66M
Immuron Business Overview & Revenue Model
Company Description
Immuron Limited, a biopharmaceutical company, researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune...
How the Company Makes Money
Immuron makes money primarily through (1) sales of its consumer/nutraceutical products and (2) funding associated with the development of its therapeutic candidates. Revenue from product sales comes from distributing and selling its immune-based c...
Immuron Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
45
Neutral
Cash Flow
30
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.05M | 7.29M | 4.90M | 1.80M | 765.19K | 145.78K |
| Gross Profit | 5.77M | 4.77M | 3.34M | 1.74M | 523.50K | -665.06K |
| EBITDA | -6.55M | -5.31M | -5.17M | -3.36M | -3.09M | -7.95M |
| Net Income | -6.01M | -5.22M | -6.94M | -3.79M | -2.85M | -8.38M |
Balance Sheet | ||||||
| Total Assets | 15.12M | 10.09M | 15.55M | 21.99M | 24.86M | 27.05M |
| Cash, Cash Equivalents and Short-Term Investments | 9.99M | 5.87M | 11.66M | 18.99M | 22.11M | 25.05M |
| Total Debt | 0.00 | 117.13K | 173.50K | 189.09K | 209.79K | 20.50K |
| Total Liabilities | 2.06M | 2.06M | 2.84M | 2.37M | 1.68M | 1.16M |
| Stockholders Equity | 13.06M | 8.03M | 12.71M | 19.62M | 23.18M | 25.90M |
Cash Flow | ||||||
| Free Cash Flow | -5.65M | -6.14M | -5.88M | -2.50M | -3.14M | -3.05M |
| Operating Cash Flow | -5.65M | -6.14M | -5.88M | -2.49M | -3.13M | -3.05M |
| Investing Cash Flow | -1.46M | -2.90M | 327.56K | -2.74M | 11.74K | -4.95K |
| Financing Cash Flow | 6.96M | 199.75K | 829.00 | -35.02K | -36.26K | 19.76M |
Immuron Technical Analysis
Positive
0.82
Price Trends
0.78
Positive
0.94
Positive
1.39
Negative
Market Momentum
0.02
Negative
68.46
Neutral
60.68
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMRN, the sentiment is Positive. The current price of 0.82 is above the 20-day moving average (MA) of 0.80, above the 50-day MA of 0.78, and below the 200-day MA of 1.39, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 68.46 is Neutral, neither overbought nor oversold. The STOCH value of 60.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IMRN.
Immuron Risk Analysis
Immuron disclosed 62 risk factors in its most recent earnings report. Immuron reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 2 New Risks
1.
If we fail to comply with the rules under the Sarbanes-Oxley Act of 2002 related to accounting controls and procedures in the future, or, if we discover additional material weaknesses and other deficiencies in our internal control and accounting procedures, the price of our ordinary shares and ADSs could decline significantly and raising capital could be more difficult. Q2, 2024
2.
A material breach in security relating to the Company's information systems and regulation related to such breaches, cyber-attacks, or other disruptions could adversely affect the Company, expose us to liability and affect our business and reputation. Q2, 2024
Immuron Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $17.30M | -4.62 | -59.29% | ― | -82.35% | -34713.73% | |
47 Neutral | $7.26M | -1.04 | -49.00% | ― | 11.90% | 43.46% | |
41 Neutral | $6.57M | -0.33 | ― | ― | ― | ― | |
| ― | $11.99M | -0.38 | -94.79% | ― | ― | 87.15% |
* Healthcare Sector Average
IMRN
Immuron
0.81
-1.07
-57.02%
CANF
Can-Fite BioPharma
2.99
-18.81
-86.28%
LPCN
Lipocine
2.29
-1.02
-30.82%
BIVI
BioVie
1.58
-6.60
-80.68%
ASBP
Aspire Biopharma Holdings
0.24
-16.72
-98.56%
Immuron Corporate Events
Immuron Secures A$1.12m R&D Tax Incentive to Support FY26 Profitability Push
Feb 17, 2026
On February 17, 2026, Immuron Limited announced it had received an Australian Government Research and Development Tax Incentive cash refund of A$1.12 million for eligible RD activities undertaken in the financial year ended June 30, 2025. The non-...
Immuron Shareholders Back Ratification of Prior Share Issues at February 2026 EGM
Feb 12, 2026
Immuron Limited reported to U.S. regulators that on 12 February 2026 its shareholders approved all resolutions put forward at an extraordinary general meeting, conducted by poll, including the ratification of prior share issues under ASX Listing R...
Immuron Reports Continued Travelan Sales Growth and ProIBS Launch in H1 FY26
Jan 20, 2026
On January 19, 2026, Immuron reported unaudited first-half fiscal 2026 global sales of AUD$4.2 million for its Travelan product, a 5% increase on the prior comparative period, with second-quarter sales up 11% sequentially to AUD$2.2 million, under...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.